• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

BRD7389

CAS No. 376382-11-5

BRD7389 ( —— )

产品货号. M26635 CAS No. 376382-11-5

BRD7389 is an inhibitor of RSK family kinase with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively.

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥624 有现货
10MG ¥859 有现货
25MG ¥1369 有现货
50MG ¥2001 有现货
100MG ¥2948 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    BRD7389
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    BRD7389 is an inhibitor of RSK family kinase with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively.
  • 产品描述
    BRD7389 is an inhibitor of RSK family kinase with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively.(In Vitro):BRD7389 (1 μM) almost completely blocked Carbachol (1 mM)-stimulated cell proliferation, but has little effect on the basal level of proliferation. BRD7389 (0.425, 0.85, 1.7, 3.4, 6.8 μM) induces insulin expression in mouse α-cells and induces a dose-dependent up-regulation of insulin (Ins2) mRNA, peaking at 0.85 μM. BRD7389 increases β-cell-specific gene expression in primary human islet cells. BRD7389 (0.85-6.8μM) significantly up-regulates Pdx1 mRNA expression in mouse α-cell line.
  • 同义词
    ——
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    ——
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    376382-11-5
  • 分子量
    366.4
  • 分子式
    C24H18N2O2
  • 纯度
    >98% (HPLC)
  • 溶解度
    ——
  • SMILES
    O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Christoph Boss,et al. Substituted sulfonylaminopyrimidines. WO2001081338A1
产品手册
关联产品
  • Bromindione

    Bromindione is a new anticoagulant.

  • Oxolamine citrate

    Oxolamine is a cough suppressant that is available as a generic drug in many jurisdictions.

  • Arundic Acid

    Arundic Acid is an astrocyte-modulating agent, delays the expansion of cerebral infarcts by modulating the activation of astrocytes through inhibition of S-100β synthesis.